Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866209 | 1.00 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL376155 | 1.00 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL2430897 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL1406056 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL376390 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL3053679 | 0.89 | LMNA (0.44) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1563474 | 0.88 | HTT (0.43) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL12404075 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL12404070 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL14440773 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-12227498-B2 | Heterocyclic amine derivative and pharmaceutical composition comprising same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-02-18 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-9937176-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | LMNA 3644/4885ALDH1A1 539/4885EPHX2 4558/4885 |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | LMNA 3472/4885ALDH1A1 3086/4885EPHX2 2881/4885 |
| US-12440496-B2 | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | NPR1, NPPA, NPR3 | LMNA 1272/4885ALDH1A1 2115/4885EPHX2 1042/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | LMNA 1186/4885ALDH1A1 3372/4885EPHX2 2600/4885 |
| US-20130245002-A1 | Triazolopyridine Compounds | FLT3, RET, MET | LMNA 3798/4885ALDH1A1 664/4885EPHX2 2359/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | LMNA 912/4885ALDH1A1 3899/4885EPHX2 2928/4885 |
| US-12227498-B2 | Heterocyclic amine derivative and pharmaceutical composition comprising same | H1-5, SSB, H1-2 | LMNA 1330/4885ALDH1A1 378/4885EPHX2 497/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | LMNA 1281/4885ALDH1A1 3684/4885EPHX2 3486/4885 |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | LMNA 1091/4885ALDH1A1 4003/4885EPHX2 3028/4885 |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | LMNA 4787/4885ALDH1A1 1360/4885EPHX2 3598/4885 |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | LMNA 3627/4885ALDH1A1 863/4885EPHX2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.